AstraZeneca - Merck's Lynparza Delays Disease Progression In Prostate Cancer Patients

  • AstraZeneca Plc AZN has reported high-level results from the PROpel Phase 3 trial of Lynparza (olaparib) in metastatic castration-resistant prostate cancer (mCRPC).
  • The data showed Lynparza plus abiraterone demonstrated improvement in radiographic progression-free survival (rPFS) versus abiraterone as a 1st-line treatment for mCRPC with or without homologous recombination repair (HRR) gene mutations.
  • Johnson & Johnson's JNJ Zytiga (abiraterone) is considered standard of care.
  • The trial also showed a trend at this interim analysis towards improved overall survival. However, the data are still immature.
  • The safety and tolerability were consistent with the known profiles of each medicine.
  • The data will be presented at an upcoming medical meeting.
  • In July 2017, AstraZeneca and Merck & Co Inc MRK collaborated to co-develop and co-commercialize Lynparza and Koselugo for multiple cancer types.
  • Price Action: AZN stock is up 1.87% at $60.59, and MRK stock is up 1.57% at $74.20 during the premarket session on the last check Friday.
Loading...
Loading...
AZN Logo
AZNAstraZeneca PLC
$73.971.31%

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Edge Rankings
Momentum
48.04
Growth
82.16
Quality
64.61
Value
21.74
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Comments
Loading...